Fusion protein and preparation method thereof, cosmetic and medicine
Through genetic engineering technology, the fusion protein is constructed and expressed, and the problem of difficulty in producing and applying type III collagen is solved, and the recombinant collagen with small molecular weight and high water-soluble has significant cell adhesion and commercialization potential.
Patent Information
- Application Number
- CN202411136877.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively produce and apply type III collagen with low molecular weight and good water solubleness, and traditional methods have potential immunogenicity and pathogenicity, which limits its application in the fields of medicine and beauty.
Through genetic engineering technology, a fusion protein is constructed, and the amino acid sequences of the 483-512 fragment and the 1232-1466 fragment of the human type III collagen chain are linked, and amino acid mutations are performed to form a recombinant type III collagen with a smaller molecular weight and high water solubility. , large-scale expression and purification using prokaryotic cells.
It has achieved a recombinant type III collagen with small molecular weight, simple synthesis, and convenient prokaryotic expression and production. It has significantly promoted cell adhesion and high temperature stability, and is suitable for commercial applications.
Smart Images

Figure CN118994416A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of cosmetics and medical devices, and in particular to a fusion protein and a preparation method thereof, cosmetics, and medicines. Background Art
[0002] Collagen is one of the most abundant structural proteins in the human body and an important component of the extracellular matrix. Type III collagen is widely distributed in soft connective tissues such as skin, fascia, and blood vessels. It is an important component involved in cortical development. Its expression level is high in infants and young children, but its content in the body will gradually decrease with age. Type III collagen in the skin is mainly distributed between the epidermis and the dermis, and plays an important role in supporting the skin, preventing skin collapse, and promoting wound healing. Collagen is widely used in the fields of beauty and medicine. The traditional method of collagen production is mainly to use animal tissues such as fur and bones for extraction after acid and alkali treatment. This method is simple to operate and low in cost, but the obtained collagen components are complex and may contain some immunogenic and pathogenic components, which limits its application in the fields of medicine and beauty. The genetic engineering method that has emerged in recent years is a method of transforming the modified collagen gene into different host cells such as Escherichia coli and Pichia pastoris, and mass producing collagen through microbial fermentation technology. The collagen obtained by this method has high purity and clear composition, which not only avoids the hidden dangers of immunogenicity and pathogenicity and has high safety; but also the structure and properties of collagen can be customized and designed according to the purpose of use.
[0003] The natural type III collagen alpha-1 chain of the human body contains 1466 amino acids and a molecular weight of about 139Kd. Mature collagen forms a mesh of collagen fibers through a spiral structure in the intercellular space, and then forms a cell matrix with other components to promote cell adhesion and support tissue structure. However, the full-length type III collagen has a large molecular weight and poor water solubility, making it difficult to be absorbed by tissues, and it is difficult to express in large quantities through genetic engineering and microbial fermentation methods. Summary of the invention
[0004] The present application provides a fusion protein and a preparation method and application thereof to solve the problems existing in the related technologies. The technical solution is as follows:
[0005] In a first aspect, an embodiment of the present application provides a fusion protein, the amino acid sequence of which comprises the amino acid sequence of the 483-512 fragment and the amino acid sequence of the 1232-1466 fragment of the alpha-1 chain of the human type III collagen chain, wherein the amino acid sequences are connected by a linker.
[0006] In one embodiment, the amino acid sequence of the 483-512 fragment is repeated multiple times.
[0007] In one embodiment, the amino acid sequence of the 483-512 fragment is repeated 4 times.
[0008] In one embodiment, the linker is GGGGSGGGG.
[0009] In one embodiment, one or more cysteines in the amino acid sequence of the fusion protein are mutated to alanine;
[0010] and / or,
[0011] The amino acid sequence has the same or similar function after one or more amino acids are substituted and / or deleted and / or added.
[0012] In one embodiment, all cysteines in the amino acid sequence of the fusion protein are mutated to alanines.
[0013] In a second aspect, an embodiment of the present application provides a nucleic acid molecule encoding the above-mentioned fusion protein, which is obtained by codon optimization of the amino acid sequence of the above-mentioned fusion protein.
[0014] In a third aspect, an embodiment of the present application provides a vector comprising the nucleic acid molecule encoding the fusion protein described above.
[0015] In a fourth aspect, an embodiment of the present application provides a host cell comprising the vector described above.
[0016] In a fifth aspect, the present invention provides a method for preparing a fusion protein, comprising the following steps:
[0017] The amino acid sequence of the fusion protein is codon-optimized to obtain a DNA sequence;
[0018] Cloning the DNA sequence into a plasmid vector;
[0019] Transforming the plasmid vector into a host cell;
[0020] The host cell is cultured to express the fusion protein.
[0021] In a fifth aspect, an embodiment of the present application provides a cosmetic comprising the fusion protein described above.
[0022] In a sixth aspect, the present application provides a drug, including the fusion protein described above.
[0023] The advantages or beneficial effects of the above technical solution include at least:
[0024] 1. A fusion protein of the present application, the amino acid sequence of the fusion protein comprises the amino acid sequence of the 483-512 fragment and the 1232-1466 fragment of the alpha-1 chain of the human type III collagen chain, and the amino acid sequences are connected by a linker. The fusion protein has a small molecular weight, simple synthesis, convenient prokaryotic expression and production, and is easier to mass produce; and the fusion protein has a significant effect of promoting cell adhesion, strong temperature stability, high efficiency, and can meet commercial applications.
[0025] 2. A method for preparing a fusion protein of the present application, wherein the amino acid sequence of the fusion protein is optimized by the host codon to form a corresponding DNA sequence; after being connected to a corresponding vector, the fusion protein is expressed by a host cell to obtain the fusion protein. The fusion protein is obtained by large-scale expression and purification of prokaryotic cells, providing a method for preparing a small molecular weight protein that is simple in preparation and easy for large-scale production.
[0026] The above summary is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments and features described above, further aspects, embodiments and features of the present application will be readily apparent by reference to the accompanying drawings and the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In the accompanying drawings, unless otherwise specified, the same reference numerals throughout the multiple drawings represent the same or similar parts or elements. These drawings are not necessarily drawn to scale. It should be understood that these drawings only depict some embodiments disclosed in the present application and should not be regarded as limiting the scope of the present application.
[0028] Figure 1 It is a schematic diagram of the structure of the fusion protein of the present application;
[0029] Figure 2 This is a diagram showing the effect of LT-RC protein purification;
[0030] Figure 3 This is a diagram showing the effect of LT-RC in promoting the adhesion of mouse embryonic fibroblasts NIH 3T3;
[0031] Figure 4 This is a diagram showing the purification effect of LT-RC (CA) protein after all cysteines in the protein sequence were mutated to alanine;
[0032] Figure 5 This is a diagram showing the effect of LT-RC (CA) in promoting the adhesion of mouse embryonic fibroblasts NIH 3T3;
[0033] Figure 6 It is the temperature stability verification diagram of LT-RC and LT-RC(CA). DETAILED DESCRIPTION
[0034] In the following, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the present application. Therefore, the drawings and descriptions are considered to be exemplary and non-restrictive in nature.
[0035] The miniaturization and water solubility of collagen molecules are important precursors for industrial applications. This application finds that, based on the primary amino acid sequence and spatial structural characteristics of human type III collagen, through genetic engineering technology, constructing recombinant type III collagen with collagen activity with a smaller molecular weight and better water solubility is a way to achieve the industrial application of collagen molecules.
[0036] Therefore, an embodiment of the present application provides a fusion protein, the amino acid sequence of which comprises the amino acid sequence of the 483-512 fragment and the amino acid sequence of the 1232-1466 fragment of the alpha-1 chain of the human type III collagen chain, and the amino acid sequences are connected by a linker.
[0037] A specific amino acid sequence fragment on the alpha-1 chain of the human type III collagen chain (uniprot sequence number: P02461) is selected for genetic recombination, and the miniaturization of the expressed collagen molecule is achieved on the basis of retaining some of the activity of the natural collagen. Therefore, compared with the full-length human type III collagen and the animal-derived collagen obtained by the traditional acid hydrolysis method, the fusion protein of the present application has a small molecular weight and high efficiency. The amino acid sequence of the 483-512 fragment of the alpha-1 chain of the human type III collagen chain is shown in SEQ ID NO.1;
[0038] SEQ ID NO. 1: GERGAPGFRGPAGPNGIPGEKGPAGERGAP.
[0039] The amino acid sequence of the 1232-1466 fragment of the alpha-1 chain of the human type III collagen chain is shown in SEQ ID NO.2:
[0040] SEQ ID NO.2:DEIMTSLKSVNGQIESLISPDGSRKNPARNCRDLKFCHP ELKSGEYWVDPNQGCKLDAIKVFCNMETGETCISANPLNVPRKHWWTDSSAEKKHVWFGESMDGGFQFSYGNPELPEDVLDVHLAFLRLLSSRASQNITYHCKNSIAYMDQASGNVKKALKLMGSNEGEFKAEGNSKFTYTVLEDGCTKHTGEWSKTVFEYRTRKAVRLPIVDIAPYDIGGPDQEFGVDVGPVCFL.
[0041] In one embodiment, the amino acid sequence of the 483-512 fragment is repeated multiple times.
[0042] In one embodiment, the amino acid sequence of the 483-512 fragment is repeated 4 times. The amino acid sequence of the 483-512 fragment repeated 4 times is shown in SEQ ID NO.3;
[0043] SEQ ID NO. 3: GERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGF RGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAP GERGAPGFRGPAGPNGIPGEKGPAGERGAP.
[0044] In one embodiment, the linker is GGGGSGGGG.
[0045] The order in which the amino acid sequence of the 483-512 fragment and the amino acid sequence of the 1232-1466 fragment are connected by a linker is not unique. The 483-512 fragment may be in front and the 1232-1466 fragment may be in the back; or the 483-512 fragment may be in the back and the 1232-1466 fragment may be in the front.
[0046] In one embodiment, when the 483-512 fragment is in front and the 1232-1466 fragment is in the back, the fusion protein has the amino acid sequence shown in SEQ ID NO.4;
[0047] SEQ ID NO.4: GERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGF RGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGGGGSGGGGDEIMTSLKSVNGQIESLISPDGSRKNPARNCRDLKFCHPELKSGEYWVDPNQGCKLDAIKVFCNMETGETCI SANPLNVPRKHWWTDSSAEKKHVWFGESMDGGFQFSYGNPELPEDVLDVHLAFLRLLSSRASQNITYHCKNSIAYMDQASGNVKKALKLMGSNEGEFKAEGNSKFTYTVLEDGCTKHTGEWSKTVFEYRTRKAVRLPIVDIAPYDIGGPDQEFGVDVGPVCFL.
[0048] In one embodiment, one or more cysteines in the amino acid sequence of the fusion protein are mutated to alanine;
[0049] and / or,
[0050] The amino acid sequence has the same or similar function after one or more amino acids are substituted and / or deleted and / or added.
[0051] Since the fusion protein of the amino acid sequence shown in SEQ ID NO. 4 contains 8 cysteines, its structure is unstable and prone to non-specific folding. Therefore, this embodiment uses amino acid mutation to improve the stability of the fusion protein and increase the possibility of its production and application.
[0052] In this embodiment, one or more cysteine residues in the amino acid sequence of the fusion protein are mutated to alanine residues. The mutation mainly occurs in the 1232-1466 fragment. The fusion protein is a protein mutated at one or more cysteine residues of C160, C166, C183, C192, C200, C270, C315, and C362. In this embodiment, the cysteine is mutated to alanine, which may be 1 cysteine mutated to 1 alanine; or 2 cysteine mutated to 2 alanines; or 3 cysteine mutated to 3 alanines; or 3 cysteine mutated to 3 alanines; or 4 cysteine mutated to 4 alanines; or 5 cysteine mutated to 5 alanines; or 6 cysteine mutated to 6 alanines; or 7 cysteine mutated to 7 alanines; wherein the position of the mutated cysteine is not particularly limited, and may be any position among C160, C166, C183, C192, C200, C270, C315, and C362. The amino acid sequences of the above fusion proteins are no longer listed one by one.
[0053] As an embodiment, all cysteines in the amino acid sequence of the fusion protein are mutated to alanine. When the 483-512 fragment is in front and the 1232-1466 fragment is in the back, the fusion protein has the amino acid sequence shown in SEQ ID NO.5;
[0054] SEQ ID NO.5: GERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGF RGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGGGGSGGGGDEIMTSLKSVNGQIESLISPDGSRKNPARNARDLKFAHPELKSGEYWVDPNQGAKLDAIKVFANMETGETAI SANPLNVPRKHWWTDSSAEKKHVWFGESMDGGFQFSYGNPELPEDVLDVHLAFLRLLSSRASQNITYHAKNSIAYMDQASGNVKKALKLMGSNEGEFKAEGNSKFTYTVLEDGATKHTGEWSKTVFEYRTRKAVRLPIVDIAPYDIGGPDQEFGVDVGPVAFL.
[0055] In this embodiment, one or more cysteine residues in the amino acid sequence of the fusion protein are mutated to alanine residues; and the amino acid sequence has the same or similar function after substitution and / or deletion and / or addition of one or more amino acids. If the substitution and / or deletion and / or addition of amino acids does not affect the function of the fusion protein, any substitution and / or deletion and / or addition of amino acids is one of the technical solutions of the present application.
[0056] In this embodiment, the amino acid sequence has the same or similar function after one or more amino acid substitutions and / or deletions and / or additions. Similarly, any amino acid substitutions and / or deletions and / or additions of the fusion protein based on the amino acid sequence of SEQ ID NO.4 do not affect the function of the fusion protein, and any amino acid substitutions and / or deletions and / or additions of the fusion protein based on the amino acid sequence of SEQ ID NO.4 are all within one of the technical solutions of the present application.
[0057] This application constructs a recombinant human-like type III collagen that can be expressed and purified on a large scale by prokaryotic cells. This protein has a significant effect on promoting cell adhesion, providing a new idea for the development of raw materials for cosmetics and medical devices, and is of great significance in the development of new cosmetics and medical devices. Compared with full-length human type III collagen and animal-derived collagen obtained by traditional acid hydrolysis, the fusion protein LT-RC provided by this application has a small molecular weight, simple synthesis, convenient prokaryotic expression and production, high efficiency, and is easier to mass produce and commercialize.
[0058] The embodiment of the present application provides a nucleic acid molecule encoding the above-mentioned fusion protein, which is obtained by codon optimization of the amino acid sequence of the above-mentioned fusion protein.
[0059] As an embodiment, the present application provides a nucleic acid molecule encoding a fusion protein of the amino acid sequence shown in SEQ ID NO.4; the sequence of the nucleic acid molecule is shown in SEQ ID NO.6, which is the amino acid sequence shown in SEQ ID NO.4 after being codon-optimized for an Escherichia coli host to form a corresponding DNA sequence;
[0060] SEQ ID NO.6:GGTGAACGCGGCGCACCAGGTTTTCGTGGTCCAGCG GGTCCGAATGGTATTCCAGGCGAAAAAGGCCCGGCAGGTGAACGTGGTGCACCAGGTGAACGTGGAGCACCAGGTTTTCGCGGTCCAGCAGGTCCGAATGGCATTCCAGGTGAGAAAGGTCCAGCAGGCGAACGTGGTGCACCTGGTGAACGCGGTGCACCAGGTTTTCGAGGTCCAGCAGGTCCGAACGGCATTCCAGGCGAAAAAGGTCCAGCAGGCGAGCGTGGTGCACCAGGTGAAAGAGGCGCACCTGGTTTTCGTGGTCCGGCAGGTCCGAACGGTATTCCGGGTGAAAAAGGTCCAGCAGGTGAACGTGGTGCTCCAGGTGGTGGTGGTTCTGGTGGTGGTGGCGATGAGATCATGACCAGCCTGAAAAGCGTGAACGGCCAGATTGAAAGCCTGATTAGCCCGGATGGCAGCCGCAAAAACCCGGCGCGCAACTGTCGTGATCTGAAATTTTGCCATCCGGAACTGAAAAGCGGCGAATATTGGGTGGATCCGAACCAGGGCTGCAAACTGGATGCGATTAAAGTGTTTTGCAACATGGAAACCGGCGAAACCTGCATTAGCGCGAACCCGCTGAACGTGCCGCGCAAACATTGGTGGACCGATAGCAGCGCGGAAAAGAAACATGTGTGGTTTGGCGAAAGCATGGATGGCGGCTTTCAGTTTAGCTATGGCAACCCGGAACTGCCGGAAGATGTGCTGGATGTGCATCTGGCGTTTCTGCGCCTGCTGAGCAGCCGTGCGTCTCAGAACATTACCTATCATTGCAAGAACAGCATTGCGTATATGGATCAGGCGAGCGGCAACGTGAAGAAAGCGCTGAAACTGATGGGCAGCAACGAAGGCGAATTCAAGGCGGAAGGCAAC AGCAAATTTACCTATACCGTGCTGGAAGATGGCTGCACCAAACATACCGGCGAATGGAGCAAAACCGTGTTTGAATATCGCACCCGCAAAGCGGTGCGCCTGCCGATTGTGGATATTGCGCCGTATGATATTGGCGGCCCGGATCAGGAATTTGGCGTGGATGTGGGCCCGGTGTGCTTTTCTG.
[0061] As an embodiment, the present application provides a nucleic acid molecule encoding a fusion protein of the amino acid sequence shown in SEQ ID NO.5; the sequence of the nucleic acid molecule is shown in SEQ ID NO.7, which is the amino acid sequence shown in SEQ ID NO.5 after being codon-optimized for an Escherichia coli host to form a corresponding DNA sequence;
[0062] SEQ ID NO.7:GGTGAACGCGGCGCACCAGGTTTTCGTGGTCCAGCG GGTCCGAATGGTATTCCAGGCGAAAAAGGCCCGGCAGGTGAACGTGGTGCACCAGGTGAACGTGGAGCACCAGGTTTTCGCGGTCCAGCAGGTCCGAATGGCATTCCAGGTGAGAAAGGTCCAGCAGGCGAACGTGGTGCACCTGGTGAACGCGGTGCACCAGGTTTTCGAGGTCCAGCAGGTCCGAACGGCATTCCAGGCGAAAAAGGTCCAGCAGGCGAGCGTGGTGCACCAGGTGAAAGAGGCGCACCTGGTTTTCGTGGTCCGGCAGGTCCGAACGGTATTCCGGGTGAAAAAGGTCCAGCAGGTGAACGTGGTGCTCCAGGTGGTGGTGGTTCTGGTGGTGGTGGCGATGAAATCATGACCAGCCTGAAAAGCGTGAACGGCCAGATTGAAAGCCTGATTAGCCCGGATGGCAGCCGCAAAAACCCGGCGCGCAATGCACGTGATCTGAAATTTGCGCATCCGGAACTGAAAAGCGGCGAATATTGGGTGGATCCGAACCAGGGCGCGAAACTGGATGCGATTAAAGTGTTTGCGAACATGGAAACCGGCGAAACCGCGATTAGCGCGAACCCGCTGAACGTGCCGCGTAAACATTGGTGGACCGATAGCAGCGCGGAAAAGAAACATGTGTGGTTTGGCGAAAGCATGGATGGCGGCTTTCAGTTTAGCTATGGCAACCCGGAACTGCCGGAGGACGTGCTGGATGTGCATCTGGCGTTTCTGCGCTTACTGAGCAGCCGCGCGAGCCAGAACATTACCTATCATGCGAAAAACAGCATTGCGTATATGGATCAGGCGAGCGGCAACGTGAAAAAGGCGCTGAAACTGATGGGCAGCAACGAAGGCGAATTCAAGGCGGAAGGCAACAGCAAATTTACCTATACCGTGCTG GAAGATGGCGCGACCAAACATACCGGCGAATGGAGCAAAACCGTGTTTGAATATCGCACCCGCAAAGCGGTGCGCCTGCCGATTGTGGATATTGCGCCGTATGATATTGGCGGCCCGGATCAGGAATTTGGCGTGGATGTGGGCCCGGTGGCATTTCTG.
[0063] The nucleic acid molecule encoding the fusion protein in the present application is connected to a vector and then transferred into a host cell, and can produce the corresponding fusion protein after expression.
[0064] Therefore, an embodiment of the present application provides a vector comprising the above-mentioned nucleic acid molecule encoding the fusion protein.
[0065] As an embodiment, the vector is connected to the nucleic acid molecule shown in SEQ ID NO.6 and / or the nucleic acid molecule shown in SEQ ID NO.7.
[0066] As an embodiment, the vector is a pET22b plasmid; the plasmid is synthesized and constructed by Suzhou Hongxun Biotechnology Co., Ltd.
[0067] An embodiment of the present application provides a host cell comprising the vector described above.
[0068] As an embodiment, the host cell includes prokaryotic cells and eukaryotic cells.
[0069] As an embodiment, the host cell is Escherichia coli; preferably, it is an E. coli BL (Rosetta) competent cell.
[0070] The present invention provides a method for preparing a fusion protein, comprising the following steps:
[0071] The amino acid sequence of the fusion protein is codon-optimized to obtain a DNA sequence;
[0072] Cloning the DNA sequence into a plasmid vector;
[0073] Transforming the plasmid vector into a host cell;
[0074] The host cell is cultured to express the fusion protein.
[0075] The amino acid sequence of the 483-512 fragment of the alpha-1 chain of human type III collagen and the amino acid sequence of the 1232-1466 fragment are combined, and the two amino acid sequences are connected by the amino acid fragment GGGGSGGGG. The above recombinant amino acid sequence is optimized by the Escherichia coli host codon to form the corresponding DNA sequence;
[0076] The step of cloning the DNA sequence into a plasmid vector is as follows: cloning the DNA sequence into a prokaryotic expression vector pET22b to form a pET22b-LT-RC plasmid, which is synthesized and constructed by Suzhou Hongxun Biotechnology Co., Ltd.
[0077] The process of transforming the plasmid vector into the host cell is as follows: transforming the synthesized pET22b-LT-RC plasmid into E. coli BL21 (Rosetta) competent cells.
[0078] Before expression, the process also includes screening strains with correct sequences: using ampicillin resistance plates to screen positive recombinants, performing colony PCR verification and DNA sequencing verification, and analyzing the sequencing results by NCBI Blast comparison; strains with correct sequencing are added with 15% glycerol and stored at -80°C.
[0079] Isopropylthiogalactoside is used to induce expression to obtain the fusion protein.
[0080] The following is a further description with reference to specific embodiments.
[0081] Example 1
[0082] Preparation of recombinant protein LT-RC
[0083] (I) Design and construction of LT-RC expression vector
[0084] The amino acid sequence of the 483-512 fragment of the alpha-1 chain of human type III collagen (uniprot sequence number: P02461) and the amino acid sequence of the 1232-1466 fragment were combined, and the two amino acid sequences were connected by the amino acid fragment GGGGSGGGG, and the amino acid sequence is shown in SEQ ID NO. 4. The above recombinant amino acid sequence was optimized by the Escherichia coli host codon to form the corresponding DNA sequence, and the sequence is shown in SEQ ID NO. 6.
[0085] The DNA sequence was then cloned into the prokaryotic expression vector pET22b (the plasmid was synthesized and constructed by Suzhou Hongxun Biotechnology Co., Ltd.). The synthesized pET22b-LT-RC plasmid was transformed into E. coli BL21 (Rosetta) competent cells, and the positive recombinants were screened on ampicillin resistance plates, and the colony PCR and DNA sequencing verification were performed. The sequencing results were analyzed by NCBI Blast. The plasmid was stored at -20°C for a long time, and the strains with correct sequencing were added with 15% glycerol and stored at -80°C. The plasmid vector pET22b has a 6*His tag, which can be used for the expression and purification of His protein. The schematic diagram of the construction of LT-RC recombinant protein is shown in the figure. Figure 1 shown.
[0086] (II) Expression and purification of LT-RC
[0087] LT-RC was induced to express using isopropylthiogalactoside (IPTG), and different IPTG concentrations, reaction temperatures and reaction times were used to explore the induction expression conditions. SDS-PAGE and Coomassie Brilliant Blue experiments were then used to determine the optimal expression conditions.
[0088] In this example, the sequenced bacteria were inoculated into TB medium containing ampicillin resistance (50 ng / μL) and cultured at 37°C overnight with shaking. The next day, the activated bacteria were inoculated into 1L fresh TB medium at a ratio of 1:100 and cultured at 37°C with shaking at 180 rpm until OD 600 =0.6, cool to 18°C, add IPTG, IPTG final concentration is 0.5mM, continue to induce expression under the same conditions for 18h, and then collect the bacterial solution. Collect the bacteria after centrifugation at 5000rpm for 30min at 4°C, resuspend and wash with 50mL ultrapure water ddH2O, and then centrifuge again to collect the bacteria. Resuspend the collected bacteria with 50mL ddH2O, and then use a high-pressure crusher to crush the bacteria with a crushing pressure of 800Pa and crushing at 4°C for 10min. The crushed solution is centrifuged at 10000rpm for 1h at 4°C, discard the precipitate, and collect the supernatant for subsequent purification.
[0089] Resuspend the supernatant obtained above with Ni-NTA agarose gel and incubate at 4°C for 2h (incubate according to 5g of bacteria: 1mL50% Ni-NTA agarose gel). The color of Ni-NTA agarose gel changes from blue to brown during the incubation process. Then, load the resuspended liquid onto the column. After the liquid in the column drips out, wash it 3 times with 1×PBS buffer containing 20mM imidazole, each time with 2 times the column volume. Then elute with 1xPBS buffer containing 300mM imidazole. If the Ni-NTA agarose gel turns blue again, it means that the elution is basically complete. Take 20uL of the eluate and keep the sample. Use 10% SDS-PAGE to detect the purification effect of the fusion protein. The eluate was then centrifuged at 10000 g for 10 min, the supernatant was collected and concentrated using a 10KD ultrafiltration tube (Millipore, catalog number: UFC900396), centrifuged at 4500 g, ultrafiltered to 500 μL at 4 ° C, and then washed with 1× PBS three times, and centrifuged three times. The concentration of the concentrated protein was measured using a BCA protein concentration detection kit (Thermo Fisher, catalog number: 23227) and stored at -80 ° C.
[0090] The purification effect of LT-RC is as follows Figure 2 As shown, the purity reaches more than 90% and can be used for subsequent experimental verification.
[0091] 2. Verification of LT-RC promoting cell adhesion
[0092] This example verifies the effect of LT-RC on cell adhesion. This effect was verified using mouse embryonic fibroblasts NIH 3T3 combined with high-resolution microscopy. The specific process is as follows: high-resolution microscopic images of mouse embryonic fibroblasts NIH 3T3 treated with different LT-RC solution concentrations are shown in Figure 2. Figure 3 shown.
[0093] (1) Ultrapure water was used to dilute the LT-RC solution (1%) with a final concentration of 10 mg / mL to different concentrations such as 1 mg / mL (0.1%) and 0.1 mg / mL (0.01%). Then, 1 mL of the above-mentioned LT-RC aqueous solution and the blank control group (ultrapure water) were added to a 6-well plate. After standing for 2 hours, the liquid was aspirated. At this time, LT-RC was successfully attached to the bottom of the well plate.
[0094] (2) An equal number (200,000) of mouse embryonic fibroblasts NIH 3T3 (from the American Model Culture Collection, catalog number: CRL-1658) were plated in the 6-well plates treated as above.
[0095] (3) Treat the cells at 37°C for 2 hours, then remove the culture medium and wash the plate once with 1× PBS, then add 1 mL of complete culture medium. Then, take photos of the cells in the different treated wells using a microscope. Figure 3 shown.
[0096] from Figure 3 It can be seen that the number of cells adhered after treatment with 0.01% LT-RC concentration was significantly higher than that of the blank control group, and with the increase of LT-RC treatment concentration, the number of cells adhered also increased significantly, and 1%
[0097] LT-RC is able to promote the adhesion of a large number of cells.
[0098] Example 2
[0099] Preparation of LT-RC products after cysteine mutation to alanine
[0100] (I) Design and construction of LT-RC cysteine mutation vector
[0101] The amino acid sequence containing 4 repeats of the 483-512 fragment of type III collagen alpha-1 chain (uniprot sequence number: P02461) and the amino acid sequence of the 1232-1466 fragment with all cysteine-alanine (CA) mutations were synthesized, and the two amino acid sequences were connected by the amino acid fragment GGGGSGGGG, and the amino acid sequence is shown in SEQ ID NO.5. The above recombinant amino acid sequence was optimized by the Escherichia coli host codon to form a corresponding DNA sequence, and the DNA sequence was shown in SEQ ID NO.7. The DNA sequence was cloned into the prokaryotic expression vector pET22b (the plasmid was synthesized and constructed by Suzhou Hongxun Biotechnology Co., Ltd.). The synthesized pET22b-LT-RC (CA) plasmid was transformed into E. coli BL (Rosetta) competent cells, and positive recombinants were screened by ampicillin resistance plates, and colony PCR and DNA sequencing were performed to verify the results, and the sequencing results were analyzed by NCBI Blast. The plasmids were stored at -20°C for a long term, and the correctly sequenced strains were added with 15% glycerol and stored at -80°C.
[0102] (II) Expression and purification of LT-RC(CA)
[0103] The expression and purification process of LT-RC(CA) after cysteine mutation is consistent with that of LT-RC. Figure 4 As shown, the purity reaches more than 90% and can be used for subsequent experimental verification.
[0104] 1. Verification of the effect of LT-RC (CA) in promoting fibroblast adhesion
[0105] This example verifies the effect of LT-RC (CA) on cell adhesion. This effect was verified using mouse embryonic fibroblasts NIH3T3 combined with high-resolution microscopy; the specific process is as follows: high-resolution microscopic images of mouse embryonic fibroblasts NIH 3T3 treated with different LT-RC (CA) solution concentrations are shown in Figure 2. Figure 5 shown.
[0106] (1) Use ultrapure water to dilute the final concentration of 10 mg / mL LT-RC (CA) solution (1%) to different concentrations such as 1 mg / mL (0.1%) and 0.1 mg / mL (0.01%). Then, take 1 mL of the above-mentioned LT-RC (CA) aqueous solution and a blank control group (ultrapure water) and add them to a 6-well plate. After standing for 2 hours, aspirate the liquid.
[0107] (2) An equal number (200,000) of mouse embryonic fibroblasts NIH 3T3 (from the American Model Culture Collection, catalog number: CRL-1658) were plated in the 6-well plates treated as above.
[0108] (3) The treated cells were cultured at 37°C for 48 hours, and then the cells in the different treated wells were photographed using a microscope. Figure 5 shown.
[0109] from Figure 5 It can be seen that the cell adhesion ability treated with 0.01% LT-RC (CA) concentration is significantly higher than that of the blank control group, and as the LT-RC (CA) concentration increases, the number of cell adhesion also increases significantly.
[0110] 2. Verification of the effect of cysteine-alanine (CA) mutation on the stability of fusion protein
[0111] This example uses UNcle protein stability analyzer to analyze the changes in temperature stability of protein molecules before and after cysteine-alanine (CA) mutation in LT-RC fusion protein. The specific process is as follows: Figure 6 shown.
[0112] (1) The protein solutions of LT-RC and LT-RC(CA) were diluted to a final concentration of 1 mg / mL using ultrapure water, followed by centrifugation at 12,000 rpm for 10 min and the supernatant was collected.
[0113] (2) 9 μL of the above protein dilution solution was respectively added to the sample tube and placed in the instrument. The detection temperature was then set to start from 25°C and increase by 1°C per minute. The Fluorescence detection module was used to record the changes in the melting temperature (Tm) and the center of mass wavelength (BCM) of the endogenous fluorescence emission spectrum, thereby analyzing the differences in the stability of LT-RC and LT-RC(CA) at different temperatures.
[0114] like Figure 6 As shown, the maximum tolerance temperature (Tm) of LT-RC (CA) protein is 87.02°C, while the maximum tolerance temperature of LT-RC protein is 69.16°C, indicating that after cysteine is mutated to alanine, the molecular stability of the fusion protein at high temperature is higher. This is because the LT-RC protein contains 8 cysteines, which makes its structure unstable and prone to non-specific folding. This example uses amino acid mutation to improve the protein stability of LT-RC, increase its production and application possibilities, and evaluate the effect of cysteine mutation on promoting the adhesion ability of fibroblasts.
[0115] Therefore, the above data show that after cysteine is mutated to alanine, LT-RC can also be successfully expressed and purified, its effect of promoting cell adhesion has not changed, and the stability of the protein molecule has been significantly increased, which will have important significance for the application of recombinant type III human collagen in medicine and cosmetics.
[0116] In summary, the present application has constructed a recombinant human-like type III collagen that can be expressed and purified on a large scale by prokaryotic cells. The protein has a significant effect in promoting cell adhesion, providing a new idea for the development of raw materials for cosmetics and medical devices, and is of great significance in the development of new cosmetics and medical devices. Compared with full-length human type III collagen and animal-derived collagen obtained by traditional acid hydrolysis, the fusion protein LT-RC provided by the present invention has a small molecular weight, simple synthesis, convenient prokaryotic expression and production, high efficiency, and is easier to mass produce and commercialize.
[0117] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples, unless they are contradictory.
[0118] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include at least one of the features. In the description of this application, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.
[0119] The above is only a specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any technician familiar with the technical field can easily think of various changes or substitutions within the technical scope disclosed in the present application, which should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.
Claims
1. A fusion protein, characterized in that The amino acid sequence of the fusion protein includes the amino acid sequence of the 483-512 fragment and the amino acid sequence of the 1232-1466 fragment of the alpha-1 chain of the human type III collagen chain, and the amino acid sequences are connected by a linker.
2. A fusion protein according to claim 1, characterized in that: The amino acid sequence of the 483-512 fragment is repeated multiple times; preferably, the amino acid sequence of the 483-512 fragment is repeated 4 times.
3. A fusion protein according to claim 1, characterized in that: The linker is GGGGSGGGG.
4. The fusion protein according to any one of claims 1 to 3, characterized in that One or more cysteines in the amino acid sequence of the fusion protein are mutated to alanine; and / or, The amino acid sequence has the same or similar function after one or more amino acids are substituted and / or deleted and / or added; Preferably, all cysteines in the amino acid sequence of the fusion protein are mutated to alanines.
5. A nucleic acid molecule encoding the fusion protein according to any one of claims 1 to 4, characterized in that: The amino acid sequence of the fusion protein according to any one of claims 1 to 4 is obtained by codon optimization.
6. A carrier, characterized in that Comprising the nucleic acid molecule of claim 5 encoding the fusion protein of any one of claims 1-4.
7. A host cell, characterized in that Comprising the vector of claim 6.
8. The method for preparing the fusion protein according to any one of claims 1 to 4, characterized in that: The following steps are involved: The amino acid sequence of the fusion protein according to any one of claims 1 to 4 is codon-optimized to obtain a DNA sequence; Cloning the DNA sequence into a plasmid vector; Transforming the plasmid vector into a host cell; The host cell is cultured to express the fusion protein.
9. A cosmetic, characterized in that: The cosmetic comprises the fusion protein according to any one of claims 1 to 4 or the fusion protein prepared by the preparation method of the fusion protein according to claim 8.
10. A drug, characterized in that The drug comprises the fusion protein according to any one of claims 1 to 4 or the fusion protein prepared by the preparation method of the fusion protein according to claim 8.
Citation Information
Cited By
Crosslinked recombinant collagen as well as preparation method and application thereof
CN118994372A
Recombinant humanized collagen composition for removing freckles as well as preparation method and application of recombinant humanized collagen composition
CN120531637A
A recombinant humanized collagen composition for removing freckles and a preparation method and application thereof
CN120531637B
Type III collagen fusion protein as well as preparation method and application thereof
CN121537530A
